<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17412" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>High Altitude Cerebral Edema</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jensen</surname>
            <given-names>Jacob D.</given-names>
          </name>
          <aff>OSF St Francis Med Center EM Residency</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vincent</surname>
            <given-names>Andrew L.</given-names>
          </name>
          <aff>University of Illinois-Peoria</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jacob Jensen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Andrew Vincent declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17412.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>High altitude cerebral edema (HACE) is a severe and potentially fatal condition associated with high altitude illness that is often thought of as a late or end-stage acute mountain sickness (AMS). It is often characterized by ataxia, fatigue, and altered mental status. HACE represents the least common form of altitude illness, however it is critical that it be rapidly diagnosed and managed, as it can progress to coma and death as a result of brain herniation within 24 hours. This activity reviews the presentation, evaluation, and management of high altitude cerebral edema and stresses the role of an interprofessional team approach to the care of affected patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Explain the importance of rapid detection of high altitude cerebral edema.</p></list-item><list-item><p>Review the history and physical exam findings typically seen in patients with high altitude cerebral edema.</p></list-item><list-item><p>Describe the treatment of high altitude cerebral edema.</p></list-item><list-item><p>Explain modalities to enhance care coordination among interprofessional team members in order to improve outcomes for patients affected by high altitude cerebral edema.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17412&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17412">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17412.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>High Altitude Cerebral Edema (HACE) is a severe and potentially fatal manifestation of high altitude illness and is often characterized by ataxia, fatigue, and altered mental status. HACE is often thought of as an extreme form/end-stage of Acute Mountain Sickness (AMS). Although HACE represents the least common form of altitude illness, it may progress&#x000a0;rapidly to coma and death as a result of&#x000a0;brain herniation within 24 hours, if not promptly diagnosed and treated.&#x000a0;<xref ref-type="bibr" rid="article-17412.r1">[1]</xref><xref ref-type="bibr" rid="article-17412.r2">[2]</xref><xref ref-type="bibr" rid="article-17412.r3">[3]</xref><xref ref-type="bibr" rid="article-17412.r4">[4]</xref></p>
      </sec>
      <sec id="article-17412.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>HACE generally&#x000a0;occurs after 2 days above 4000m but can occur at lower elevations (2500m) and with faster onset. &#x000a0; Some, but not all, individuals will suffer from symptoms of AMS such as headache, insomnia, anorexia, nausea prior to transitioning to HACE. &#x000a0;Some may also have concomitant High Altitude Pulmonary Edema (HAPE). &#x000a0;HACE in isolation is rare, but the absence of concomitant HAPE or symptoms of AMS prior to deterioration does not rule-out the presence of&#x000a0;HACE. &#x000a0;&#x000a0;<xref ref-type="bibr" rid="article-17412.r5">[5]</xref><xref ref-type="bibr" rid="article-17412.r6">[6]</xref><xref ref-type="bibr" rid="article-17412.r7">[7]</xref></p>
      </sec>
      <sec id="article-17412.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Incidence of HACE is 0.5-1% at altitudes of 4000-5000 m. &#x000a0;HACE affects those of all ages and genders, though younger males may be at&#x000a0;higher risk due to continuation of ascent despite symptoms of AMS and faster rate of ascent. Risk factors include prior history of high altitude illness, lack of acclimatization, heavy physical exertion, rapid rate of ascent, and abrupt ascent from lower altitudes.&#x000a0;</p>
      </sec>
      <sec id="article-17412.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Although the exact mechanism of development of HACE is not fully understood, it is thought to be the extreme form/end-stage of AMS. Hypoxia at altitude elicits neuro-hormonal (VEG-F, Nitric Oxide, reactive cytokines, free radicals) and hemodynamic responses resulting in hypoxia-induced cerebral vasodilation leading to over perfusion of microvascular cerebral beds. &#x000a0;This leads to intracranial hypertension with elevated capillary pressure and capillary leakage. The disruption of the blood-brain&#x000a0;barrier from these stressors leads to subsequent cerebral edema. &#x000a0;The &#x0201c;tight fit&#x0201d; hypothesis suggests that one&#x02019;s susceptibility to AMS/HACE is dependent upon the individual&#x02019;s intracranial space available to compensate for increasing edema. This theory would help to explain the seemingly&#x000a0;random nature of AMS that can evolve into HACE. &#x000a0;The &#x0201c;revised theory&#x0201d; to the development of HACE argues against volume overload and intracranial hypertension as the leading cause. &#x000a0;In this model, hypoxia induces free radical formation causing damage/failure of the Na+/K+ ATPase Pump with resultant astrocyte swelling from osmotic-oxidative stress, with subsequent cytotoxic edema. Neither theory is considered the standard by which HACE is fully understood.</p>
      </sec>
      <sec id="article-17412.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Most cases develop as a progression of AMS and will include a history of recent ascent to altitude and prior complaints/findings of AMS including a headache, fatigue, nausea, insomnia, and/or lightheadedness. &#x000a0;Some may also have signs/symptoms of HAPE. &#x000a0;Transition to HACE is heralded by signs of encephalopathy including ataxia (usually the earliest clinical finding) and altered mentation which may range from mild to severe. &#x000a0;Other symptoms may include a more severe headache, difficulty speaking, lassitude, a&#x000a0;decline in the level of consciousness, and/or focal neurological deficits or seizures.</p>
      </sec>
      <sec id="article-17412.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>HACE is a clinical diagnosis with the patient typically presenting with signs of encephalopathy, preceeded by signs and symptoms of Acute Mountain Sickness. The onset of neurological findings such as progressive decline in cognitive/mental function, declining level of consciousness, impaired coordination, slurred speech, and/or lassitude signify the transition from AMS to HACE. &#x000a0;Typical evaluation consists of an abnormal neurological exam, with ataxia often being the earliest finding. Early symptoms may be misinterpreted as exhaustion and it is important to exclude these, as well as other disorders such as dehydration, hypoglycemia, hypothermia, or hyponatremia which all may have signs and symptoms that overlap with that of HACE. &#x000a0;Though rarely available, laboratory testing may show an elevated white blood cell count in the setting of HACE, whereas any number of metabolic abnormalities may be present with the aforementioned others within the differential diagnosis. &#x000a0;Lumbar puncture may have an increased opening pressure with otherwise normal laboratory findings. CT may show cerebral edema, but MRI is a better study to evaluate for more subtle signs of edema and can remain abnormal for days up to weeks. &#x000a0;To date, there has been no direct correlation with the severity of edema with clinical outcome.</p>
      </sec>
      <sec id="article-17412.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>The mainstay of treatment is the immediate descent of at least 1000m or until symptoms improve. One should not descend alone and should have assistance to minimize physical exertion, which may worsen the patient&#x02019;s condition. If descent is not an option, one may use a portable hyperbaric chamber and/or supplemental oxygen to temporize illness, but this should never replace or delay evaluation/descent when possible. If available, dexamethasone 8mg for one dose, followed by 4mg every 6 hours should be given to adults via PO, IM, or IV routes. Pediatric dosing is 0.15 mg/kg every 6 hours. Acetazolamide has proven to be beneficial in only a single clinical study. The suggested dosing regimen for Acetazolamide is 250 mg PO, given twice daily. Though effective in alleviating or temporizing symptoms, none of the adjunct treatment modalities are definitive or a replacement for an immediate descent.<xref ref-type="bibr" rid="article-17412.r8">[8]</xref><xref ref-type="bibr" rid="article-17412.r1">[1]</xref><xref ref-type="bibr" rid="article-17412.r9">[9]</xref></p>
      </sec>
      <sec id="article-17412.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <list list-type="bullet">
          <list-item>
            <p>Acute psychosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Brain tumour</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Carbon monoxide poisoning</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Central nervous system infection</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cerebrovascular bleed or infarct</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cerebrovascular spasm</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic ketoacidosis</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hypoglycemia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hyponatremia</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Ingestion of drugs</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Seizure disorder</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-17412.s10" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Acclimatization is the best means by which to prevent HACE and all other forms of AMS. &#x000a0;Considerations for prevention of AMS and subsequent HACE is to have a slow rate of ascent with the altitude one sleeps at being more important than the altitude reached. &#x000a0;Final ascent rates of 300-500m per day are recommended for safe and preventative acclimatization. &#x000a0;If signs of AMS develop, stop ascent and if debilitating or severe, descend immediately. &#x000a0; Prophylaxis for HACE/AMS includes both Acetazolamide and Dexamethasone. Ibuprofen is recommended for those with a history of altitude illness. There is less evidence for natural remedies such as ginkgo balboa and coca leaves. &#x000a0;Most advocate training regimens and slow rate of ascent to optimize acclimatization. &#x000a0;This often requires an intense time commitment and is difficult for many to achieve, particularly for those engaged in recreational climbing. Some studies have shown benefit to sleeping in specialized tents at home that provide normobaric hypoxia before departure to higher altitudes, although this has not been validated as a primary preventative measure of AMS or HACE. &#x000a0;</p>
      </sec>
      <sec id="article-17412.s11" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>High Altitude Cerebral Edema (HACE) is a severe and potentially fatal manifestation of high altitude illness and&#x000a0;is often characterized&#x000a0;by ataxia, fatigue, and altered mental status.&#x000a0;HACE is often thought&#x000a0;of as an extreme form/end-stage of Acute Mountain Sickness (AMS). Although HACE represents the least common form of altitude illness, it may progress&#x000a0;rapidly to coma and death&#x000a0;as a result&#x000a0;of&#x000a0;brain herniation within 24 hours, if not promptly diagnosed and treated. The condition is best managed by an interprofessional team that includes a neurologist, internist and an emergency department physician</p>
        <p>Even with robust&#x000a0;training regimens, acclimatization, and prophylactic medications, HACE can strike any individual at any altitude, at any time. Even those with considerable experience at altitude may fall prey to the wares of HACE. Thus careful attention to the signs and symptoms of AMS and HACE should always be given proper consideration and respect.&#x000a0;</p>
      </sec>
      <sec id="article-17412.s12">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17412&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17412">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/wilderness-and-environmental/high-altitude-cerebral-edema/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=17412">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17412/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17412">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17412.s13">
        <title>References</title>
        <ref id="article-17412.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gonzalez Garay</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Molano Franco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nieto Estrada</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;-Carvajal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Arevalo-Rodriguez</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing high altitude illness: Part 2. Less commonly-used drugs.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Mar</month>
            <day>12</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD012983</fpage>
            <pub-id pub-id-type="pmid">29529715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nieto Estrada</surname>
                <given-names>VH</given-names>
              </name>
              <name>
                <surname>Molano Franco</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Medina</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Gonzalez Garay</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;-Carvajal</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Arevalo-Rodriguez</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2017</year>
            <month>Jun</month>
            <day>27</day>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>CD009761</fpage>
            <pub-id pub-id-type="pmid">28653390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r3">
          <label>3</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Jensen</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <chapter-title>High Altitude Cerebral Edema</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">28613666</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khodaee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grothe</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Seyfert</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>VanBaak</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Athletes at High Altitude.</article-title>
            <source>Sports Health</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>126</fpage>
            <page-range>126-32</page-range>
            <pub-id pub-id-type="pmid">26863894</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>deWeber</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The athlete and high altitude.</article-title>
            <source>Curr Sports Med Rep</source>
            <year>2010</year>
            <season>Mar-Apr</season>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>79</fpage>
            <page-range>79-85</page-range>
            <pub-id pub-id-type="pmid">20220348</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gallagher</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>PH</given-names>
              </name>
            </person-group>
            <article-title>High-altitude illness.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2004</year>
            <month>May</month>
            <volume>22</volume>
            <issue>2</issue>
            <fpage>329</fpage>
            <page-range>329-55, viii</page-range>
            <pub-id pub-id-type="pmid">15163571</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Basnyat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Murdoch</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>High-altitude illness.</article-title>
            <source>Lancet</source>
            <year>2003</year>
            <month>Jun</month>
            <day>07</day>
            <volume>361</volume>
            <issue>9373</issue>
            <fpage>1967</fpage>
            <page-range>1967-74</page-range>
            <pub-id pub-id-type="pmid">12801752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Research advances in pathogenesis and prophylactic measures of acute high altitude illness.</article-title>
            <source>Respir Med</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>145</volume>
            <fpage>145</fpage>
            <page-range>145-152</page-range>
            <pub-id pub-id-type="pmid">30509704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17412.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zafren</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pun</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regmi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bashyal</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gautam</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamarkattel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lamichhane</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Acharya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basnyat</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>High altitude illness in pilgrims after rapid ascent to 4380&#x000a0;M.</article-title>
            <source>Travel Med Infect Dis</source>
            <year>2017</year>
            <season>Mar-Apr</season>
            <volume>16</volume>
            <fpage>31</fpage>
            <page-range>31-34</page-range>
            <pub-id pub-id-type="pmid">28285976</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
